Jason Palopoli, MD
Hematology & Oncology · Newark, DENPI 1053625632
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Onmark, Inc. accounts for 93.8% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $4,057, more than ten times the $95 reported in 2019. Among hematology & oncology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $221.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Onmark, Inc.$4K
- Seagen Inc.$95
- AstraZeneca$42
- Syndax Pharmaceuticals, Inc.$29
- Merck$25
- Beone Medicines USA, Inc.$22
- plus $50 from 3 others
What the payments were for
- Travel & lodging$2,48559%
- Food & beverage$1,59438%
- Education$1073%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Onmark, Inc. | 10 | $3,944 |
| Seagen Inc. | 1 | $95 |
| AstraZeneca | 2 | $42 |
| Syndax Pharmaceuticals, Inc. | 1 | $29 |
| Merck | 1 | $25 |
| Beone Medicines USA, Inc. | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Incyte Corporation | 1 | $18 |
| Gilead | 1 | $12 |
How this compares
$4,206 in reported general payments places this provider in the 90th percentile of 26 hematology & oncology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 90 | $1,193,387 |
| RevlimidLenalidomide | 26 | $623,758 |
| ImbruvicaIbrutinib | 25 | $437,528 |
| PomalystPomalidomide | 20 | $427,251 |
| PromactaEltrombopag Olamine | 13 | $172,899 |
| Imatinib Mesylate | 39 | $148,415 |
| OrgovyxRelugolix | 27 | $70,631 |
| Abiraterone Acetate | 12 | $41,925 |
| EliquisApixaban | 34 | $31,438 |
| XareltoRivaroxaban | 23 | $26,631 |
| Oxycodone Hcl | 59 | $1,282 |
| Acyclovir | 28 | $932 |
| Bicalutamide | 24 | $714 |
| Ondansetron Hcl | 58 | $654 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $438 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Newark
- Dhaval ShahNewark$10K
- Jamal MislehNewark$2K
- Evan LapinskyNewark$2K
- Kathiresan SuppiahNewark$2K
- Nicole LaslettNewark$1K
- Sujung ParkNewark$1K
- Ramya VaradarajanNewark$901
- Palak ShahNewark$750
- Amy McGheeNewark$646
- Philip MargiottaNewark$521
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.